INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

MDGLMADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 54
Max Insider Score33
Connections9with evidence

MDGL · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$199K
368 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    BALLARD PARTNERSLDA Q1 2026 first quarter · Pharmacy · Aug 26, 2026
  • ← Lobbied forevidence
    CAPITOL COUNSEL LLCLDA RR 2026 first quarter · Health issues, MED, Medicare/Medicaid · Aug 26, 2026
  • ← Lobbied forevidence
    CROSSROADS STRATEGIES, LLCLDA Q2 2026 second quarter · Medicare/Medicaid, Health issues · Aug 26, 2026
4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL
$652K
1,202 sh
Sep 11, 2026
Sep 11, 2026
traded Sep 11, 2026
+0d
SEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$837K
1,539 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$415K
761 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$66K
120 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$280K
520 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$87K
160 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

0
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$32K
60 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$69K
131 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$184K
347 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$277K
522 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$196K
368 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$273K
512 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$212K
396 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$345K
644 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$558K
1,040 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$344K
640 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$116K
215 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

7
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$273K
505 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$196K
362 sh
Sep 9, 2026Sep 11, 2026
traded Sep 9, 2026
+2dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$57K
106 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$117K
218 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

1
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$86K
160 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

4
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$371K
687 sh
Sep 11, 2026Sep 11, 2026
traded Sep 11, 2026
+0dSEC FORM 4

Evidence

16
LS
Levy Richard SDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise
M$66K
4,000 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

18
HC
Huntsman CaroleChief Commercial Officer
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$167K
340 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

25
HC
Huntsman CaroleChief Commercial Officer
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$282K
570 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

33
SJ
Sibold William JohnDirector, President and CEO
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale
SELL$777K
1,577 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

30
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale
SELL$319K
647 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

9
LS
Levy Richard SDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise
M—
4,000 sh
Jan 26, 2026Jan 26, 2026
traded Jan 26, 2026
+0dSEC FORM 4

Evidence

0
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
18.4K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

10
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$43K
80 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$216K
400 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

10
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$22K
40 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$217K
400 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

0
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$4,424
280 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$154K
280 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

0
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M—
280 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

9
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Option exercise · 10b5-1 plan
M$387K
24.5K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$758K
1,480 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$561K
1,094 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$692K
1,345 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.03M
1,996 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$396K
766 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.27M
2,450 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$707K
1,363 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$440K
846 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$355K
681 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$438K
840 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$507K
970 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$628K
1,199 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.28M
2,432 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$561K
1,066 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$822K
1,560 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$304K
575 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$366K
691 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$88K
166 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$149K
280 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$177K
332 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$79K
148 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Levy Richard SDirector · Jan 26, 2026
  • ← Insider ofevidence
    Huntsman CaroleChief Commercial Officer · Jan 26, 2026
  • ← Insider ofevidence
    Friedman Paul ADirector · Jan 13, 2026
  • ← Insider ofevidence
    Taub RebeccaDirector · Jan 13, 2026
  • ← Insider ofevidence
    Sibold William JohnDirector, President and CEO · Dec 4, 2025

    • Lobbying

    $760K reported · de-duplicated
    2026 Q2 $380K in-house2026 Q1 $380K in-house
    • CROSSROADS STRATEGIES, LLC$50K2026 Q1 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid
    • CAPITOL COUNSEL LLC$60K2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • BALLARD PARTNERS$120K2026 Q2 · posted Aug 26, 2026 · Pharmacy
    • CAPITOL COUNSEL LLC—2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • CAPITOL COUNSEL LLC$60K2026 Q2 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid
    • BALLARD PARTNERS$120K2026 Q1 · posted Aug 26, 2026 · Pharmacy
    • In-house report$380K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • In-house report$380K2026 Q1 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues
    • CROSSROADS STRATEGIES, LLC$50K2026 Q2 · posted Aug 26, 2026 · Medicare/Medicaid, Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.